Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Withdrawal of NRTIs in virologically suppressed, treatment-experienced HIV-1 patients with NRTI resistance
2012-000198-21Phase 4Completed
- Sponsor
- Fight AIDS and Infectious Diseases Foundation
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lamivudine, emtricitabine, zidovudine, stavudine, tenofovir and 2 more in Human immunodeficiency virus infection type 1 and human immunodeficiency virus infection (HIV) (2 arms), sponsored by Fight AIDS and Infectious Diseases Foundation. Primary endpoint: Proportion of subjects with plasma HIV-1 RNA <50 copies/mL at 48 weeks. Started Mar 2012; status: completed.
02
Drugs
lamivudineemtricitabinezidovudinestavudinetenofovir
03
Conditions
Human immunodeficiency virus infection type 1human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2012-000198-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000198-21.